SEC Form 4 · accession 0001104659-26-073614
Humacyte, Inc. · HUMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathleen Sebelius
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 5:56 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001818382
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1 | $1.08 | Jun 11, 2026 | A | 80,000 | A | — | Jun 11, 2036 | Common Stock | 80,000 | 80,000 | D |
Explanation of responses
- F1The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.